Lovastatin
Brand names: Altoprev, Lovastatin
Part of: Statins
At a glance
- Medicare prescriptions, 2024
- 1,979,543
- Medicare drug cost
- $19.5M
- Average cost per prescription
- $9.85
- Clinicians who prescribed it
- 70,888
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies.)
From the FDA-approved prescribing information (label dated February 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 42.3%
- Internal Medicine 30.5%
- Nurse Practitioners 15.0%
- Physician Assistants 5.1%
- Cardiology 1.5%
- Geriatric Medicine 1.4%
- General Practice 1.3%
- Interventional Cardiology 0.6%
- Hospitalist 0.3%
- Endocrinology & Diabetes 0.3%
- Nephrology (Kidney) 0.2%
- Pediatrics 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 35% from 2019 to 2024.
Biggest change by state since 2019
- Utah −19%
- Idaho −24%
- Vermont −25%
- Connecticut −26%
- New Hampshire −27%
- Puerto Rico (smallest change) −54%
- Florida (smallest change) −41%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bluepoint Laboratories
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | green oval tablet, 6 mm | LU G01 |
| 20 mg | green round tablet, 6 mm | LU G02 |
| 40 mg | green round tablet, 8 mm | LU G03 |
Boswell Pharmacy Services LLC D/b/a Bps Wholesale
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | white round tablet, 10 mm | CTI 143 |
Lupin Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | green oval tablet, 6 mm | LU G01 |
| 20 mg | green round tablet, 6 mm | LU G02 |
| 40 mg | green round tablet, 8 mm | LU G03 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | white round tablet, 10 mm | CTI 143 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | white round tablet, 10 mm | CTI 143 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.